Alnylam Pharma (ALNY) Misses Q2 EPS by 42c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Alnylam Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Period Activity
July 28, 2022 8:00 AM EDTAchieved Second Quarter 2022 Global Net Product Revenues of $214 Million for ONPATTRO®, GIVLAARI®, and OXLUMO® (33% Growth vs. Same Period Last Year)
Received FDA Approval of AMVUTTRA (vutrisiran) for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults
Expects to Report Topline Results from APOLLO-B Phase 3 Trial of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy Within the Next Three Weeks
Reiterated 2022 Financial Guidance, Including Combined Net Product Revenues of $870-$930 Million
CAMBRIDGE, Mass.--(BUSINESS... More
